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Purpose: Intimal hyperplasia plagues all types of  vascular intervention. Early confluent 
reendothelialization may attenuate the smooth muscle cell (SMC) proliferative response. 
We previously reported that fibroblast growth factor type 1 (FGF-1) and heparin at 
relative concentrations of 10 ng/ml :250 U /ml  delivered in a fibrin glue (FG) suspension 
can selectively stimulate endothelial cells (EC) and inhibit SMC proliferation in cell 
culture. This current study evaluates this surface treatment with and without seeded 
autologous ECs on intimal hyperplasia in a canine carotid artery balloon injury model. 
Methods: Twenty-nine adult dogs underwent bilateral balloon injury to a 6 cm segment of 
their carotid arteries. The injury resulted in a reproducible removal of  the intima and 4 to 6 
medial amellae. Nine dogs were used in part I to determine the percent retention of  FGF-1 
and EC when applied in a FG suspension to the balloon-injured carotid arteries. Part 2 used 
the remaining 20 dogs to determine the effect of  this surface treatment on intimal hyperpla- 
sia. In 10 group I dogs, FG (fibrinogen 32.1 mg/ml  and thrombin 0.32 U/ml)  containing 
FGF-1 (11 ng/ml) and heparin (250 U/ml)  was applied to the luminal surface of  one carotid 
artery, whereas the contralateral carotid artery underwent balloon injury alone. In 10 group 
I I  dogs, an identical FG preparation with FGF-1 and heparin was applied to the surface of  
one carotid artery, whereas the contralateral carotid artery received FG/FGF-1/heparin that 
also contained autologous ECs (P3; 5 x 10 ~ to 10 x 104 cells/cm2). Five dogs from both 
group I and group I I  were killed at 10 days and the remaining 10 dogs at 30 days. Histologic 
analysis and computerized morphometric analysis were used to determine intimal and medial 
thickness and area, percent endothelialization, and medial SMC proliferative rate. 
Results: There was no measurable neointima in any 10-day dog. There was no difference in 
neointimal area between the treatments in group I 30-day dogs. There was a significant 
decrease in maximal neointimal area, intima/media thickness ratio, and infima/media rea 
ratio in group I130-day dogs that were treated with FG/FGF- 1/heparin plus EC. There was 
an insignificant increase in percent EC coverage and an insignificant decrease in medial SMC 
proliferative rate in group I I  10-day dogs treated with FG/FGF-1/heparin plus EC. 
Conclusions: In this canine carotid model, FG with FGF-1 and heparin did not induce 
significant intimal or medial thickening after 10 or 30 days when compared with vessels that 
were only balloon-injured. The seeding of  autologous ECs within the FG/FGF-1/heparin 
suspension caused a reduction in neoinfima formation with no concomitant medial thicken- 
ing 30 days after injury.~The use of FG to locally deliver FGF-1 and ECs may have clinical 
relevance in the inhibition of intimal hyperplasia. (J Vasc Surg 1997;25:840-9.) 
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Intimal hyperplasia continues to be a major prob- 
lem in all types of vascular intervention. After intimal 
injury, vascular smooth muscle cells (SMCs) prolifer-. 
ate and migrate to the deendothelialized vessel sur- 
face, where they continue to proliferate and secrete 
extracellular matrix proteins. In many instances, the 
resultant neointima can lead to vessel stenosis. In 
theory, early confluent reendothelialization may re- 
duce SMC proliferation, migration, or both. 1 Acidic 
fibroblast growth factor (aFGF or FGF-1) has been 
shown to stimulate reendothelialization 2 a d inhibit 
intimal thickening of deendothelialized rat carotid 
arteries. 3 Our laboratory has shown enhanced endo- 
thelialization of canine thoracoabdominal and aor- 
toiliac expanded polytetrafluoroethylene (ePTFE) 
grafts coated with fibrin glue (FG) containing FGF-1 
and heparin when compared with grafts coated with 
FG alone or uncoated grafts. 2,4 Heparin was used in 
the FG because it protects FGF-1 from proteolytic 
inactivation by thrombin and potentiates FGF-I's 
mitogenic activity for endothelial cells (ECs). Hepa- 
rin has also bcen shown to inhibit intimal hyperplasia 
in an injured rat carotid model by inhibiting SMC 
proliferation and migration, s In vitro cell culture 
studies in our laboratory have demonstrated that 
FGF-1 and heparin, suspendcd in FG in a relative 
concentration ratio of 10 ng/ml to 250 U/ml, can 
selectively stimulate EC proliferation and inhibit 
SMC proliferation. 6 The overall goal of this experi- 
ment was to determine the feasibility and effective- 
ness of using FG to affix FGF-1 and heparin as well as 
seeded ECs onto balloon-injured canine carotid ar- 
teries and to determine whether FG containing 
FGF-1 and heparin either with or without seeded 
autologous ECs would have an effect on intimal 
hyperplasia that occurs after balloon injury. 
METHODS 
The experiment was divided into two parts. In 
part 1, we determined the percent retention after in 
vivo perfusion of FGF-1 and of EC both applied 
within FG onto balloon-injured canine carotid arter- 
ies. In part 2, we determined the effect of this surface 
treatment on intimal hyperplasia. 
EC harvest and culture methods. Thirteen 
dogs (three in part 1 and 10 in part 2) underwent 
bilateral external jugular vein harvest (3 weeks before 
the carotid balloon injury) and were then allowed to 
awaken. The veins were everted, placed into Hanks 
balanced salt solution (Ca ++ and Mg ++ free, pH 8.0; 
Gibco, Grand Island, N.Y.), and then centrifuged at 
800 revolutions per minute for 10 minutes to re- 
move red blood cells. The veins were placed sequen- 
tially into prewarmed 0.05% Trypsin-0.53 mmol/L 
ethylenediamine tetraacetic acid (EDTA) and colla- 
genase (Gibco), 100U/ml, for 10 minutes each. 
After discarding the veins, the Trypsin-EDTA and 
collagenase solutions were centrifuged at 1000 revo- 
lutions per minute for 10 minutes. The supernatants 
were discarded, and 5 ml of growth media (M-199 
[Gibco] supplemented with 10% fetal bovine serum 
[Hyclone, Logan, Utah], 10 ng of FGF-1 [American 
Red Cross], 100 U/ml  penicillin, streptomycin 100 
~g/rnl [Gibco], and bovine heparin 5 U/ml  
[Lymphomed, Melrose Park, Ill.]) was added to the 
combined cell suspensions from both tubes. The 
combined cell suspension was added to a fibronectin- 
coated T-25 culture flasks (2.5 ~g/cm 2) and incu- 
bated at 37°C in a 5% humidified CO2 chamber. 
The growth media was changed after 24 hours and 
then every 2 to 3 days. 
The cultured ECs underwent Trypsin-EDTA 
passage after reaching confluence. Three passages 
were performed to eventually ield nine confluent 
T-75 culture flasks. A hemocytometer was used to 
determine cell number/flask (approximately 5 mi]- 
lion cells/T-75 flask). Factor VIII immunoperoxb 
dase staining (Dako Corp., Carpenteria, Calif., and 
Vector Laboratories, Burlingame, Calif.) was per- 
formed between the second and third passage to 
confirm the identity and purity of the EC culture. 
FG preparation with and without EC. An FG 
solution was used in part 1 and part 2 of the experi- 
ment. FG/FGF-1/heparin was prepared by mixing 
human fibrinogen 32.1 mg/ml (American Red 
Cross) with porcine heparin 250 U/ml  (LypoMed, 
Inc., Melrose Park, Ill.) and recombinant FGF-1 11 
ng/ml (American Red Cross) and then adding hu- 
man thrombin 0.32 U/ml  (American Red Cross ) in 
volumes equivalent to twice that of the calculated 
volume ofa 6 cm carotid segment (1.8 ml). For the 
dog carotid arteries undergoing EC seeding, 1 × 107 
to 3 × 107 EC in 0.5 ml NS were added to the 
FG/FGF-1/heparin solution. Just before fibrinogen 
polymerization i to fibrin (8 to 10 minutes), the 
FG/FGF-1/heparin with or without ECs was in- 
jected into the carotid artery. A 3F embolectomy 
catheter was used to remove xcess glue after 8 min- 
utes. 
Perioperative care. Twenty-nine healthy adult 
mongrel dogs were used in both part I (nine dogs) 
and part II (20 dogs). Each dog was allowed a 
2-week conditioning period before undergoing any 
surgical procedure. Preoperative platelet aggregom- 
etry was used to determine the inherent endency 
towards-thrombosis in these dogs according to our 
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Fig. 1. Canine carotid balloon injury and FG application 
model. 
previously described method. 7 Briefly, 20 ml of 
blood was drawn, and baseline aggregometry in re- 
sponse to adenosine diphosphate (ADP, 2 × 10 -s 
mol/L) was performed in a dual-channel Bio Data 
Platelet Aggregation Profiler (BioData Corp., Hat- 
boro, Pa.). A positive aggregation study was defined 
as either greater than 60% platelet response to ADP 
or an aggregation 40% above that to the saline con- 
trol. All dogs were medicated with aspirin 81 rag/ 
day and dipyridamole 25 mg three times per day for 
3 days before surgery and for 14 days after surgery. 
Platelet aggregation studies were repeated on the day 
of surgery and on the day the dogs were killed. 
General anesthetic was used for all surgical proce- 
dures. Dogs were fasted overnight and then anesthe- 
tized with thiopcntal sodium (30 mg/kg). After en- 
dotracheal intubation, the dogs were placed on 
volume control ventilators and maintained under an- 
esthesia with 1% halothane and nitrous oxide (to 
effect). Cefazolin 500 mg was administered intrave- 
nously before and after surgery. Potassium chloride 
solution was used to kill the dogs after carotid har- 
vest. Animal care complied with the "Principles of 
Laboratory Animal Care" (formulated by the Na- 
tional Society for Medical Research) and the Guide 
for the Care and Use of Laboratory Animals (NIH 
Publication No. 86-23, revised 1985). 
Bilateral carotid balloon injury. All of the 
dogs in part 1 and part 2 of the experiment under- 
went bilateral carotid balloon injury (Fig. 1). M'ter 
being placed under anesthesia, bilateral longitudinal 
neck incisions were made and the carotid arteries 
were exposed from the base of the neck to the origin 
of the external carotid artery (approximately 12cm). 
A 6 cm segment of the carotid artery was marked 
with a 7-0 Prolene suture. After systemic hepariniza- 
tion, vascular control was obtained. A transverse ar- 
teriotomy was made in the proximal carotid artery 
(proximal to the 6 cm segment), and an intimal 
injury was made by making three passes with an 
inflated 4F thromboembolectomy balloon catheter 
throughout the length of the 6 cm carotid segment. 
Preliminary experiments demonstrated that the bal- 
loon injury resulted in a reproducible r moval of four 
to six medial lamellae. 
For carotid arteries that underwent balloon injury 
alone, the arteriotomy was then closed with running 
6-0 Prolene suture and perfusion was restored. For 
carotid arteries being treated with FG/FGF-1/hep- 
arin with or without EC, an 18F angiocath was 
placed through the arteriotomy and controlled with 
a Rummel tourniquet. Just before the polymeriza- 
tion of fibrinogen into fibrin, the FG preparation was 
instilled into the carotid artery after placing a distal 
clamp 6 cm from the proximal tourniquet. The FG 
preparation was allowed to adhere to the vessel wall, 
and after 8 minutes luminal patency was restored by 
removing excess FG polymer from the vessel lumen 
using a 3F Fogarty thromboembolectomy catheter. 
This smaller 3F-diameter catheter was gently pulled 
through the vessel such that no visible distention was 
observed, unlike that seen with the larger 4F catheter 
used to create the injury. The arteriotomy was closed 
with running 6-0 Prolene and perfusion was re- 
stored. The deep layers of the neck incision were 
closed with absorbable suture, and the sldn was 
closed with interrupted nylon suture. 
Part 1:FGF-1 and EC retention. Nine of the 
29 adult mongrel dogs underwent bilateral carotid 
balloon injury as previously described. Six dogs had 
bilateral application of FG with 12SI-FGF-1 and hep- 
arin. One carotid artery was immediately excised 
from these dogs. The remaining carotid artery was 
perfused for 10 minutes (n = 3) or 60 minutes (n = 
3) and then excised. The three remaining dogs were 
treated with unlabeled FG/FGF- 1/heparin but with 
the addition of ll lln_labele d canine jugular EC ( 10 s 
to 106 cell/cm 2) harvested from these dogs 3 weeks 
earlier. These dogs also had one carotid artery 
immediately excised and had perfusion restored to 
the remaining carotid artery for 60 minutes. All 
explanted carotid segments were gently flushed 
with 10 ml NS, gamma counted (Packard Auto 
Gamma 5650, Packard Instrument Co., Downers 
Grove, Ill.), and then opened longitudinally and 
photographed. Computerized planimetry was per- 
formed using Sigma Scan (Jandel Scientific Corte 
Madera, Calif.). Counts per minute (CPM)/mm 2
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Table I. FGF-1 and EC retention 
CPM/mm 2 % Retention 
Treatment Acute 20 rain. perfusion 60 rain. perfusion 0 to 60 minutes 
i2SI-FGF-1 24.9 ± 6,4 10.2 + 3.2* 8.74 + 3.81" 37.4 + 12.2 
~I~In-EC 5501 ± 590 N/A  1125 ± 458~ 20.4 ± 6.4§ 
*p < 0.001 for acute vs 10 min. 
~p = NS (0.34) for 10 min vs 60 min. 
~p < 0.05 for acute vs 60 rain. 
§p < 0.05 for FGF-1 vs EC 60 rain. retention. 
and percent retention were determined for FGF-1 
and EC. 
Part 2: intimal hyperplasia nd medial SMC 
proliferation. The 20 remaining dogs (10 of which 
had undergone xternal jugular vein resection and 
EC harvest) underwent bilateral balloon injury as 
previously described. Group I consisted of 10 clogs 
that were treated with FG containing FGF-1 and 
heparin on one side, whereas the contralateral ca- 
rotid artery received balloon injury alone. The 10 
group II dogs were treated with FG/FGF-1/heparin 
on one side, whereas the contralateral carotid artery 
received FG/FGF-1/heparin also containing autol- 
ogous  EC  (P3,  5 X 104 to  10  X i04ce l l s /cm2) .  
Carotid artery harvest was performed immedi- 
ately before the dogs were killed at 10 and 30 days. 
Five dogs from group I and from group II were killed 
at 10 days, and the remaining dogs were ldlled at 30 
days. The dogs received intramuscular injections of 
5-bromodeoxyuridine (BrdU), 90 mg/kg,  divided 
into three doses at 24, 16, and 8 hours before they 
were killed. At the time of death, the clogs were 
reanesthetized and their incisions reopened. The ca- 
rotid arteries were pressure-perfused in situ with 4% 
paraformaldehyde and then removed. The vessels 
were opened longitudinally, divided in half length- 
wise, and divided into proximal, middle, and distal 
segments. Specimens for hematoxylin and eosin 
(H&E) staining and electron microscopic examina- 
tion were preserved in 1% glutaraldehyde/4% para- 
formaldehyde solution. Specimens destined for im- 
munohistochemical staining were transferred from 
the 4% paraformaldehyde and placed into 70% EtOH 
after 24 hours. 
Intimal thiclmess and area measurements and 
percent endothelialization. H&E-stained sections 
from the middle segments were analyzed for intimal 
hyperplasia. Computerized morphometric analysis 
was performed using the Bioquant BQ OS/2 (Bio- 
metrics Inc., Nashville, Tenn.) to determine maximal 
intimal thiclmess and area and medial thiclmess and 
area. The wvo thickest areas of each longitudinal 
section were measured for neointimal and media 
thiclcness at 25×. Maximal intimal and medial area 
were measured at 6.3× at this thickest point and 
then normalized for length. The maximal intima/ 
media thickness and intima/media rea ratios were 
then calculated. 
H&E microscopic evaluation and scanning elec- 
tron microscopic evaluation (Jeol JSM 6300.XV, To- 
kyo, Japan) were used to determine the percent cov- 
erage of ECs in the longitudinal carotid sections. 
SMC proliferative rate. Immunoperoxidase 
staining using a standard two-antibody system 
against BrdU was performed to identify actively di- 
viding medial SMCs. The slides were lightly counter- 
stained with hematoxylin to identify all cell nuclei. 
Two blinded observers counted the strongly positive 
BrdU cells in the inner half of the media of 10 high 
power field (HPF; 40×), every 1000 Ixm along the 
length of the longitudinal section. If a HPF was 
unreadable because of artifact or oblique cut of the 
section, a new HPF was counted 1000 Ixm away. 
Using an eyepiece grid, the total number of SMCs in 
the inner half of each HPF was counted and a prolif- 
erative rate (number of positive BrdU cells/total 
SMCs × 100) was calculated. Small bowel sections 
were used as positive controls. 
Data analysis and statistics. All data are ex- 
pressed as a mean + standard eviation. Statistical 
analysis was based on a population size o fn  = 5, and 
significance was defined by a p value less than 0.05. 
Statistical calculations were performed on a corn- 
puter using the SigmaStat for Windows software 
(Jandel Scientific, Corte Madres, Calif.). Intimal 
thicl~ess and area comparisons and percent endo- 
thelialization were done using a paired t test. SMC 
proliferative rates were compared using a repeated 
measures analysis of variance test. 
RESULTS 
There were no significant perioperative complica- 
tions related to the carotid injury, and all of the dogs 
survived until vessel harvest. All of the injured carotid 
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Table II. Group I 30-day intimal hyperplasia 
Max. intimal Max. medial 
Max. intimal Max. medial Max. area × 102 area X 102 Max. 
thickness thickness intimal/medial (~m 2) per (~m 2) per intimal/medial 
(~m) (Ixm) thickness mm length mm length area ratio 
Injury alone 92.4 -- 28 275.3 + 53.1 0.34 + 0.09 70.0 +- 29.6 296 + 79.5 0.23 + 0.07 
Injury + FG/FGF-1 /Hep 92.0 _+ 40.8 253.0 _+ 42.3 0.39 + 0.26 55.9 +- 21.8 278 -+ 45.9 0.22 + 0.14 
Table II I .  Group II 30-day intimal hyperplasia 
Max. intimal Max. medial 
Max. intimal Max. medial Max. area × 102 area × 103 Max. 
thickness thickness intimal/medial (izm 2) (ixm 2) intimal/medial 
(~zm) (ixm) thickness ratio per mm length per mm length area ratio 
Injury + FG/FGF-1/hep 76.8 -+ 26.7 291.8 _+ 30.0 0.26 -+ 0,08 56~1 -+ 22.3 318 _+ 66.6 0.17 _+ 0.07 
Injury + FG/FGF-1 /Hep + EC 43.1 -+ 30.0~ 299.7 _+ 45.4 0.14 -+ 0,09* 30.6_+ 17.5" 314 _+ 58.5 0.10 -+ 0.06* 
*p < 0.05 comparing injury + FG/FGF-1/hep vs injury + FG/FGF-1/hep + EC. 
~p = 0.06 comparing injury + FG/FGF=I /hep  vs injury + FG/FGF-1/hep + EC. 
segments were patent at harvest. There were also no 
significant differences in in vitro platelet aggregom- 
etry between the dogs in the different reatment 
groups. 
FGF-1 and EC retention. After FG application 
and excess FG removal, there was a significant rapid 
release of 125I-FGF-1 from the FG in the first 10 
minutes of perfusion, resulting in 41% retention of 
the labeled growth factor (24.9 -+ 6.4 CPM/mm 2 to 
10.2 + 3.2 CPM/mm2; Table I). After 60 minutes 
there was a 37.4 + 12.2% retention of FGF-1 (NS 
when compared with 10 minutes). The ECs in FG 
demonstrated significantly ess retention than FGF- 1 
on the balloon-injured carotid arteries after 60 min- 
utes ofperfusion. The 20.4 +_ 6.4% retention of ECs 
after 60 minutes resulted in a retained EC density of 
2 × 103 to 20 × 103 cell/cm 2(90% to 95% of the FG 
plus mIn-ECs are removed with the 3F balloon, 
followed by the additional 79.6% loss during the 60 
minute perfusion). 
Neointimal thickness and area and percent 
endothelialization. There was no consistent, mea- 
surable neointimal formation in any lO-day dog. 
There appeared to be increased surface cellularity in 
the carotid arteries that underwent EC seeding. At 
30 days there was no statistically significant difference 
in maximal intimal thickness or area in the group I 
dogs (injury alone vs injury plus FG/FGF-1/hepa- 
fin; Table II). Thcre was a significant decrease in 
maximal intimal area, intima/media thickness, and 
intima/mcdia rea ratio in the group II dogs that 
were treated with FG/FGF-1/heparin plus autolo- 
gous seeded ECs when compared with those dogs 
that received injury alone and dogs that received 
injury plus FG/FGF-1/heparin alone (Table III, 
Fig. 2). There were no significant differences in any 
of media thickness or media areas between any of the 
groups. 
The percent cndothelialization f the carotid sur- 
faces was determined. The group I 10-day carotid 
arteries treated with injury alone had a percent EC 
coverage of 54.6% ___ 23.7% vs 33.8% + 36.4% EC 
coverage of the carotid arterics that were treated with 
FG/FGF-1/heparin (p = NS). The group II 10-day 
carotid artery treated with FG containing FGF-1 and 
heparin had a percent EC coverage of 18.2% _+ 
18.8% vs 47.0% -+ 36.6% EC coverage of the carotid 
arteries that were treated with FG/FGF-1/heparin 
and seeded ECs (p = NS). The group I 30-day dogs 
demonstrated a percent EC coverage of 77.0% + 
15% (injury alone) vs 84.0% + 19% (injury plus 
FG/FGF-1/heparin; p = NS). The 30-day group II 
dogs showed apercent EC coverage of 71.2% + 18% 
(injury plus FG/FGF-1/heparin) vs 92.8% + 9% 
(injury plus FG/FGF- 1/heparin plus EC; p = 0.17). 
SMC proliferative rate. The results of the me- 
dial SMC proliferative rates are depicted in Fig. 3. At 
10 days after balloon injury there were no statistically 
significant differences in the SMC proliferative rates 
between the differently treated carotid arteries in 
each group. The overwhelming majority of prolifer- 
ating SMCs were located in the inner half of the 
media (Fig. 4). There was a trend towards enhanced 
SMC prolifcration in the carotid arteries that re- 
ceived FGF-1 in the group I dogs (7.95% + 4.63%) 
vs the injury alone (6.05% -2-- 5.27%; p = 0.06), 
Furthermore, there was a trend towards diminished 
SMC proliferation in the carotid arteries that were 
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Injury Alone lnj. + FG/FGF-I/Hep. Inj. + FG/F(;F-I/Hep. + EC 
Fig. 2. H&E photomicrographs depict longitudinal sections of balloon-injured canine carotid 
arteries (original magnification, 25 ×). Arrows indicate internal elastic lamina. Note decreased 
neointimal formation in balloon-injured carotid artery treated with FG/FGF-1/heparin plus 
EC. 
treated with FG containing FGF-1/heparin plus au- 
tologous ECs (3.52% + 3.53% vs 5.06% -+ 3.24%; 
p = 0.26). A regression curve portraying the inverse 
relationship between percent EC coverage and SMC 
proliferation of the group II 10-day carotid explants 
is shown in Fig. 5. There was no statistical difference 
in the total number of medial SMCs per HPF be- 
tween each treatment group (range, 130 to 147 
medial SMCs/HPF). 
DISCUSSION 
The control of intimal hyperplasia fter vascular 
intervention would ultimately lead to higher long- 
term patency rates for all types of arterial reconstruc- 
tion. Many investigators have sought o pharmaco- 
logically directly inhibit neointimal formation by 
locally or systemically providing various SMC growth 
inhibitors, antiplatelet medications, antiinflamma- 
tory agents, immunosuppressants, calcium channel 
blockers, and angiotensin-convcrting e zyme inhib- 
itors in an attempt to specifically decrease SMC mi- 
gration and proliferation. Our laboratory has tried to 
reduce the SMC hyperplastic response u ing SMC 
growth inhibitors as well and also in a more indirect 
fashion by enhancing EC reendothelialization by 
providing an optimal environment for angiogenesis. 
ECs have been shown to influence SMC function 8 
and recently have been shown to modulate three= 
dimensional SMC morphologic features in part by 
inhibiting TGF-[3] activation. 9 
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Fig. 3. Ten-day medial SMC proliferative rate deter- 
mined by BrdU staining. 
Complete reendothelialization d es not occur in 
animal or human vessels after long-segment balloon 
injury. Theoretically, the early presence of a quies- 
cent, confluent, endothelial monolayer after intimal 
injury would retard SMC proliferation and migra- 
tion. Clowes has Shown that early endothelial regen- 
eration after hydrostatic stretch injury reduces SMC 
migration. 10 Other studies have shown that EC seed- 
ing reduces platelet deposition in a canine carotid 
endarterectomy odel at 5 hours; 1, 2, 3, and 4 days; 
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Fig. 4. BrdU immunohistochemical st ining of transverse section of balloon-injured canine 
carotid artery treated with FG/FGF-1/heparin (original magnification, 10 × ). Note "positive" 
proliferating cells in inner half of media. 
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Fig. 5. Regression curve for medial SMC proliferation 
versus increasing EC coverage for group II 10-day carotid 
explants. 
and 4 weeks. 11 Our model evaluated whether FGF-1 
plus heparin with or without seeded ECs could re- 
duce intimal hyperplasia in a carotid balloon injury 
model. Wc evaluated endothelial coverage and SMC 
proliferation to determine whether these factors were 
relatedto neointimal formation. 
Our results show that FG can be usedas a veh cle 
to deliver both FGF- i  and EC onto balloon-injured 
vessels. FG, made from relatively low thrombin con- 
centrations (<32 U/ml  ) is degraded by intrinsic 
fibrinolytic systems. Surface coating of FG has been 
shown not to cause increased platelet deposition as 
compared with ePTFE or balloon deendothelialized 
arteries not treated with FG. 12'13 The major imprac- 
tical aspect of the FG delivery system is that the 
majority of the FG along with e growth factors and 
the seeded ECs within the FG are removed by the 
balloon catheter that is used to restore arterial pa- 
tency. Initial adherence and retention rates could be 
improved with better delivery devices (i.e., catheter 
spray devices) to decrease the large number of initial 
ECs now required to effectively seed the carotid 
arteries. 
Previous canine experiments performed in our 
laboratory showed that FGF-1 and heparin increased 
inner capsule thickness on treated ePTFE grafts. 2,4 In 
these prior studies, heparin was used to protect 
FGF-1 from circulating proteases and thrombin and 
to enhance its mitogenic effect on ECs. In this exper- 
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iment, we changed the relative concentration of 
FGF-1 and heparin from our graft experiments (in- 
crease in heparin) in an attempt to reproduce our in 
vitro experiments, which showed an inhibition of 
SMC proliferation and a stimulation of EC prolifera- 
tion using a ratio ofFGF- 1 :heparin of 11 ng/ml:500 
U/ml.  Heparin has been shown to reduce SMC 
proliferation and migration in a rat carotid injury 
model but not in a baboon artery injury model. 5,14 
Heparin, therefore, was required in this experiment 
to protect FGF-1, and there was a potential benefit 
with respect o heparin's SMC inhibitory effect. 
In this experiment, FGF-1 + heparin did not 
produce an increase in intimal or medial thickness 
when compared with carotid arteries that were only 
balloon-injured. However, FGF-1 with heparin 
alone had no inhibitory effect on intimal hyperplasia. 
The effect of FGF-1 is uncertain. Bjornson showed 
that when given intravenously, FGF-1 does inhibit 
intimal thickening and promote ndothelial regener- 
ation over injured areas. 3 However, Nabel demon- 
strated in an in situ transfection model that FGF-1 
induced intimal thickening in porcine arteries 21 
days after,genc transfer) 5 Our model of transient 
FGF- 1 activity differs from Nabel's direct gene trans- 
fer model where FGF-1 was persistently overex- 
pressed. We placed FGF-1 in the FG in an attempt to 
create ideal conditions for EC proliferation. 
In this experiment, we evaluated maximal intimal 
thickness in longitudinal sections. Wc were thereby 
able to assess intimal hyperplasia nd percent EC 
coverage along the entire injured and noninjured 
carotid arteries in a continuous fashion. Preliminary 
experiments in which acutely injured and treated 
carotid arteries were cut in transverse sections did not 
show any regional difference in the delivery of the FG 
suspension to the circumference of the vessel when 
evaluated under low-power and high-power magnifi- 
cation. Qualitative histologic analysis of cross-sec- 
tions of the experimental carotid arteries did not 
suggest adifference in the magnitude or variability of 
intimal thickness or EC coverage as compared with 
sections cut in the longitudinal axis. 
In our canine model, the addition of seeded ECs 
to the FG/FGF-1/heparin did decrease maximal in- 
timal thickness and intimal area in the balloon-in- 
jured carotid segments. The vessel surface in these 
EC-seeded carotid arteries appeared to be more cel- 
lular, and there was an insignificant trend towards 
enhanced endothelial coverage at 10 and 30 days in 
these EC-sceded carotid arteries. This lack of signifi- 
cance may in part result from the relatively high 
percent of EC coverage in the group that received 
injury alone. At 30 days most of the artery surface is 
covered by ECs regardless of the initial treatment 
after balloon injury. 
Although there was no significant difference in 
SMC proliferative rates in the groups, there was a 
trend towards a reduction in SMC proliferation in 
the carotid arteries that were treated with FG/FGF- 
1/heparin plus autologous ECs. Analyzing the data 
in individual dogs, there appeared to be an inverse 
relationship between EC coverage and SMC prolifer- 
ative ratcs. The lowest 10-day SMC proliferative 
rates (2.6% and 4.7%) were found in carotid arteries 
that demonstrated the grcatest percent coverage with 
ECs. If it were possible to evaluate 10-day percent 
endothelialization a d SMC proliferation and 30- 
day neointimal thickness in the same dog, it would 
have been possible to determine whether there was a 
direct relationship among these variables in our 
model. 
The difference in percent endothelialization a d 
SMC proliferation in the injury plus FG/FGF-1 /  
heparin-treated arteries of groups I and I][ is thought 
to reflect interanimal variability. The data was there- 
fore analyzed only by comparing the two treatment 
protocols within the groups rather than between the 
groups. 
Thc use of FG with FGF-1 and heparin in the 
absence of seeded ECs showed neither a net benefi- 
cial nor detrimental effect on endothelialization, 
SMC proliferation, or myointimal hyperplasia. The 
addition of ECs resulted in a decreased neointimal 
thiclmess. On the basis of our previous in vitro data 
that showed EC proliferation in response to FGF-1 
and heparin within FG, it is likely that the presence of 
these factors within FG may promote EC growth in 
vivo. Future studies will compare EC growth in FG 
with and without FGF-1 and heparin when applied 
to injured arteries. 
The results of this experiment suggest hat the 
EC may exert an inhibitory effect on SMCs. The 
results are not simply a result of the FG's mechanical 
separation of medial SMC from blood because the 
diminished neointimal formation was not present on 
the vessels that were treated with FG plus FGF/  
heparin without ECs. Cultured ECs have been 
shown to secrete various ubstances that inhibit SMC 
migration and proliferation. 16,17 Our laboratory's 
EC/SMC co-culture xperiments demonstrated de- 
creased SMC proliferation i  the presence of conflu- 
ent ECs when compared with nonconfluent ECs 
(unpublished ata, Lin P, Hirko M, Greisler HP). 
ECs may also theoretically influence intimal hyper- 
plasia by inhibiting SMC migration and extracellular 
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matrix deposit ion. A l though we could not  demon-  
strate a significant increase in EC coverage in the 
FG/FGF-1 /hepar in  plus EC group, these carotid 
arteries presumably had more ECs on their injured 
surface immediately after bal loon injury. Perhaps if 
we had evaluated our dogs at earlier times after in- 
jury, we might  have seen a significant beneficial effect 
o f  EC seeding on EC coverage or on SMC prolifera- 
tive rates. 
CONCLUSION 
This experiment demonstrated that FG can effec- 
tively immobi l ize a growth factor, FGF-] . ,  and ECs 
onto injured arterial surfaces. This delivery system 
may be applicable to clinical situations in which a 
local, high concentrat ion o f  a substance or cells is 
required to elicit a desired biologic effect. This exper- 
iment also demonstrated an inhibitory effect o f  EC 
seeding on neoint imal formation after intimal injury. 
The use o f  EC seeding in FG may have clinical 
implications in the reduct ion o f  intimal hyperplasia 
that occurs after vascular intervention. 
We acknowledge Jacqueline Garfield for the electron 
microscopic preparation. 
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DISCUSSION 
Dr. Dolores F. Cikrit (Indianapolis, Ind.). I would 
like to compliment Drs. Zarge and Greisler on this nice 
study, which again demonstrates the importance of the 
ECs. One of the past presidents of this Society, Dr. 
Malcolm Herring, was one of the first to investigate the 
concept of endothelial seeding. It is interesting that even 
though 90% to 95% of the ECs from the FG mixture 
were removed, when the excess FG was removed from 
the vessel and more than 80% of the remaining cells were 
lost during the first hour of profusion, th~it the few 
remaining cells exerted the effect that they were able to 
demonstrate. 
Some investigators have demonstrated intimal thicken- 
ing with FGF-1. Is the FGF necessary? 
The SMC proliferation rate at 10 days was not signifi- 
cantly affected by the treatment. What was the smooth 
muscle proliferative r sponse at 30 days? How much endo- 
thelial coverage was present at 30 days? Were they conflu- 
ent? Did you see greater EC coverage than what has been 
demonstrated with other endothelial seeding techniques? 
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Dr. Joseph I. Zarge. We believe that FGF-1 is neces- 
sary for this experiment to create an optimal environment 
for ECs to proliferate and attain confluence. A confluent 
quiescent EC monolayer has been shown to have really 
beneficial properties in inhibiting platelet deposition and in 
secreting factors that may inhibit intimal hyperplasia. 
With regard to the SMC proliferative rates at 30 days, 
those results are pending; however, my impression is that 
there will be a significant reduction in all of the SMC 
proliferative rates so that the differences between the 
groups will be very small. Dr. Clowes' data with a rat 
carotid balloon injury model showed that after 10 days the 
SMC proliferative rates were back to preinjury baseline 
levels. 
Concerning EC coverage, we have just finished evalu- 
ating this at both 10 and 30 days using both H&E and 
scanning electron microscopy. In the group II dogs, the 
carotid arteries that were seeded with autologous ECs had 
47% and 92.8% EC coverage at 10 and 30 days, respec- 
tively, compared with 18.2% and 77% EC coverage in the 
group II carotid arteries that were not initially seeded with 
ECs. Although these differences did not attain statistical 
significance, there was a trend towards enhanced and sus- 
tained EC coverage in these seeded carotid arteries. 
